GCAT and prostate adenocarcinoma: In our risk signature, we found that the low-risk genes NUCB1 and GCAT were higher in tumor tissues than in adjacent normal tissues in PRAD; however, their expression levels in the high stage were lower than those in the low stage and that the risk signature performed well in prognosis prediction.